🇺🇸 FDA
Patent

US 9731011

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

granted A61KA61K31/704A61K35/74

Quick answer

US patent 9731011 (Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
EnGeneIC Molecular Delivery Pty Ltd
Grant date
Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/704, A61K35/74, A61K38/217, A61K39/3955